Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 989

4.

Bioidentical hormone therapy: a panacea that lacks supportive evidence.

Boothby LA, Doering PL.

Curr Opin Obstet Gynecol. 2008 Aug;20(4):400-7. doi: 10.1097/GCO.0b013e3283081ae9.

PMID:
18660693
5.

Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.

L'hermite M, Simoncini T, Fuller S, Genazzani AR.

Maturitas. 2008 Jul-Aug;60(3-4):185-201. doi: 10.1016/j.maturitas.2008.07.007. Epub 2008 Sep 5. Review.

PMID:
18775609
6.

Hormone replacement therapy in menopausal women: Past problems and future possibilities.

Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS.

Gynecol Endocrinol. 2006 Oct;22(10):564-77. Review.

PMID:
17135036
8.

Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women.

de Lignières B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, Kuttenn F.

Climacteric. 2002 Dec;5(4):332-40.

PMID:
12626212
9.

Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.

Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM.

Breast Cancer Res Treat. 2007 Jan;101(2):125-34.

PMID:
16841178
10.

Breast cancer risk with postmenopausal hormonal treatment.

Collins JA, Blake JM, Crosignani PG.

Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. Epub 2005 Sep 8. Review. Erratum in: Hum Reprod Update. 2006 May-Jun;12(3):331.

PMID:
16150813
11.

Bioidentical hormones.

Well E.

Adv Nurse Pract. 2009 Sep;17(9):37-8, 40-1. No abstract available.

PMID:
20000171
12.

Bioidentical hormone therapy: a review.

Boothby LA, Doering PL, Kipersztok S.

Menopause. 2004 May-Jun;11(3):356-67. Review.

PMID:
15167316
13.

A review of the cardiovascular and breast actions of drospirenone in preclinical studies.

Simoncini T, Genazzani AR.

Climacteric. 2010 Feb;13(1):22-33. doi: 10.3109/13697130903437375. Review.

PMID:
19938948
14.

[Hormone replacement therapy and cancer of the breast. 1. Does replacement therapy increase the risk of cancer of the breast?].

Ayres de Campos D, Barros H, Martinez de Oliveira J.

Acta Med Port. 1997 Oct;10(10):697-703. Review. Portuguese.

15.

Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.

Johansen OE, Qvigstad E.

Adv Ther. 2008 Jun;25(6):525-51. doi: 10.1007/s12325-008-0070-6. Review.

PMID:
18568306
16.

Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.

Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR.

Gynecol Endocrinol. 2009 Dec;25(12):807-15. doi: 10.3109/09513590903056878. Review.

PMID:
19906000
17.

Breast cancer risk in postmenopausal women using estrogen-only therapy.

Lyytinen H, Pukkala E, Ylikorkala O.

Obstet Gynecol. 2006 Dec;108(6):1354-60.

PMID:
17138766
18.

Progestins and breast cancer.

Eden J.

Am J Obstet Gynecol. 2003 May;188(5):1123-31. Review.

PMID:
12748456
19.

Supplemental Content

Support Center